https://www.selleckchem.com/pr....oducts/ly2880070.htm
Lenvatinib has proven efficacy in progressive, radioiodine- (RAI-) refractory thyroid cancer (TC). Dose reductions are commonly performed due to decreased tolerability and adverse effects. This retrospective multicenter study analyzed overall survival (OS) and progression-free survival (PFS) and tolerability in the Austrian patient population treated with lenvatinib. Clinical data of 43 patients (25 males and 18 females) with a median age of 70 years (range 39-91 years) and RAI-refractory TC with metastases to the lymph nodes (74%), l
Like
Comment
Share
